Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of cardiorenal events in people with type 2 diabetes at high cardiovascular risk or with chronic kidney disease. However, their effect ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Non-Commercial (NC): Only non-commercial uses of the work are permitted. No ...

SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits on the evolution and progression of cardiomyopathy and nephropathy, which is characterized by a reduction in ...

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are disease-modifying agents in type 2 diabetes mellitus (T2DM) and CKD, but studies on their use in cirrhosis are limited. We aimed to assess the ...

Henan Key Laboratory of High Efficiency Energy Conversion Science and Technology, Henan International Joint Laboratory of New Energy Materials and Devices, School of Physics and Electronics, Henan ...

HealthDay News — Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study published online March 17 in ...

One new feature tracks a user's meals, with the help of photos, and the other tracks the user's glucose intake. There's no exact release date for these new features. The meals feature allows users ...

We aimed to evaluate the effects of sodium/glucose cotransporter 2 inhibitors (SGLT2is) on coagulation function and explore their potential role in regulating coagulation in these patients. Methods: ...

Oura is introducing two new features, Meals and Glucose, to the Oura app. Meals uses AI to analyze tracked food and offer nutrient breakdowns and guidance. Glucose integrates Dexcom’s Stelo ...